Monitoring Guidelines for Erectile Dysfunction
All men with erectile dysfunction should undergo baseline laboratory monitoring including fasting glucose-lipid profile and morning total testosterone (within the last 12 months), with cardiovascular risk assessment being mandatory given ED's role as a strong independent predictor of future cardiac events 1, 2, 3.
Initial Baseline Assessment
Mandatory Laboratory Tests
- Fasting glucose and lipid profile - ED shares common risk factors with cardiovascular disease, and this screening is non-negotiable 1, 3
- Morning total testosterone (if not assessed in last 12 months) - Low testosterone contributes to ED and requires specific treatment 1, 3
- Bioavailable or free testosterone if total testosterone is borderline or clinical hypogonadism is suspected 1
Cardiovascular Risk Communication
The diagnosis of ED provides a pivotal opportunity for cardiovascular intervention. ED symptoms typically present 3 years earlier than coronary artery disease symptoms 2. You must communicate this increased cardiovascular risk to:
- The patient
- Their partner
- The primary care provider for appropriate referrals and interventions 2
Treatment Monitoring with PDE5 Inhibitors
Optimizing First-Line Therapy
When prescribing PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil):
- Verify proper medication use and timing in nonresponders before declaring treatment failure 1
- Titrate the dose to provide optimal efficacy - this is a strong recommendation 2
- Provide explicit instructions to maximize benefit including timing relative to sexual activity and need for sexual stimulation 2
- Target erection hardness of Grade 4 on the Erection Hardness Score (completely hard and fully rigid) - this correlates with optimal intercourse satisfaction, psychosocial benefits, and treatment satisfaction 4
Common Pitfall
Education about proper dosing and the requirement for sexual stimulation can restore effectiveness in apparent nonresponders 1. Don't abandon PDE5 inhibitors without confirming correct usage.
Monitoring for Specific Populations
Hypogonadal Men on Testosterone Therapy
If testosterone supplementation is initiated:
- Monitor hemoglobin levels - increased risk of polycythemia
- Monitor serum transaminases - hepatotoxicity risk
- Monitor prostate-specific antigen (PSA) - increased risk of prostate adenocarcinoma 5
These require interval monitoring throughout treatment duration.
Indications for Specialized Diagnostic Testing
Advanced monitoring is reserved for specific scenarios 1:
- Primary ED (not caused by acquired organic disease or psychogenic disorder)
- Young patients with pelvic/perineal trauma who could benefit from revascularization
- Penile deformities requiring surgical correction (Peyronie's disease, congenital curvature)
- Complex psychiatric or psychosexual disorders
- Complex endocrine disorders
- Medicolegal reasons (e.g., before penile prosthesis implantation)
Specialized Tests Include:
- Nocturnal penile tumescence and rigidity (Rigiscan)
- Intracavernous vasoactive drug injection
- Penile dynamic duplex ultrasonography
- Specialized endocrinological studies
- Specialized psychodiagnostic evaluation 1
Treatment Response Assessment
Quantitative assessment of erection hardness using the 4-point Erection Hardness Score should be used to monitor treatment response 4. A shift from EHS 3 (hard enough for penetration but not fully hard) to EHS 4 (completely hard and fully rigid) correlates with:
- Significant improvements in intercourse satisfaction
- Enhanced relationship satisfaction
- Improved self-esteem and confidence
- Greater treatment satisfaction 4
Ongoing Monitoring Strategy
For men on stable PDE5 inhibitor therapy without complications, no routine laboratory monitoring is required beyond the initial cardiovascular and endocrine assessment. However, any change in cardiovascular status, development of new symptoms, or treatment failure warrants reassessment of both the ED management and underlying cardiovascular risk factors 2, 3.